Current Price
Target Price
Analyst Sentiment
9 ratings: Buy
Seaport Therapeutics, Inc. (SPTX) is a pioneering biopharmaceutical firm dedicated to advancing cutting-edge immune-oncology therapies to meet critical unmet medical needs, particularly in the field of oncology. The comp...|
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
| Metric (B) | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2027 | FY 2027 |
|---|---|---|---|---|---|---|
| $-3.88 | $-0.66 | $-0.56 | $-0.53 | $-0.57 | $-2.39 | |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| — | -8.7% | +1.7% | +13.2% | +8.8% | +7.1% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | KKorsana Bi... | KRSA | $1.44B | — | 3.66 | — | — | — | — |
| 2. | KKardigan I... | KARD | $1.29B | — | 2.10 | — | — | — | — |
| 3. | AAlto Neuro... | ANRO | $1.18B | — | 4.00 | — | — | -46.70% | — |
| 4. | LLB Pharmac... | LBRX | $1.39B | — | 3.33 | — | — | -38.80% | — |
| 5. | LLycia Ther... | LYCA | $1.63B | — | — | — | -762.00% | — | — |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Mar 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 | 0.35 | 0.36 |
Gross Profit | 0 | 0 | 0 | 0 | -0.35 | -0.36 |
Gross Profit % | - | - | - | - | - | - |
| 16.18 | 25.44 | 27.2 | 27.54 | 65.46 | 29.99 | |
EBIT | -16.18 | -25.44 | -27.2 | -27.54 | -65.81 | -30.34 |
OPM % | - | - | - | - | - | - |
Non-Operating Income | 3.09 | 2.99 | 3.58 | 2.65 | 0 | 3.91 |
PBT | -13.09 | -22.45 | -23.62 | -24.89 | -62.59 | -26.43 |
Income Tax | 0 | 0 | 0 | 0 | 0.01 | -0.04 |
Tax Rate % | - | - | - | - | -0.02% | 0.14% |
Net Income | -13.13 | -22.54 | -24.14 | -25.41 | -62.6 | -26.39 |
NPM % | - | - | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2024 | Dec 2025 |
|---|---|---|
Revenue | 0 | 0 |
COGS | 0 | 0 |
Gross Profit | 0 | 0 |
Gross Profit % | - | - |
| 52.42 | 87.29 | |
EBIT | -52.42 | -87.29 |
OPM % | - | - |
Non-Operating Income | 5.54 | 13.19 |
PBT | -46.88 | -74.11 |
Income Tax | 0 | 0 |
Tax Rate % | - | - |
Net Income | -46.88 | -74.88 |
NPM % | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2024 | Dec 2025 |
|---|---|---|
| 309.1 | 46.04 | |
| 0 | 187.61 | |
| 0 | 0 | |
| 0 | 0 | |
| 6.68 | 15.36 | |
Total Assets | 315.78 | 249.01 |
| 0 | 0 | |
| -24.85 | -92.55 | |
| 0 | 0 | |
| 4.73 | 2.01 | |
| 335.89 | 339.55 | |
Total Liabilities | 315.78 | 249.01 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2024 | Dec 2025 |
|---|---|---|
| -29.63 | -77.94 | |
| 0 | 0 | |
| 339.3 | -0.87 | |
Net CFNet Cash Flow | 309.67 | -78.81 |
FCFFree Cash Flow | -29.74 | -78.3 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2024 | Dec 2025 |
|---|---|---|
| - | 127.6% | |
| - | - | |
| 27.82 | 17.46 | |
| - | 0.00 | |
Cash Conversion | 0.63 | 1.04 |
Payout Ratio | - | - |
| - | - | |
| - | - | |
| - | - | |
| 2.00 | 1.00 | |
| - | - | |
| - | - | |
| - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns Seaport Therapeutics Inc, from SEC filings
No SEC ownership filings for this company yet.
Seaport Therapeutics Inc's SEC filings and earnings call transcripts
No SEC filings for this company yet.
What recent news says about Seaport Therapeutics Inc, scored for sentiment.